Page 39 - GPD-3-3

Gene & Protein in Disease Modulating immune response in liver by curcumin

RAGE, the receptor for advanced glycation end products. doi: 10.1016/j.atherosclerosis.2013.10.016
J Mol Med (Berl). 2005;83:876-886.
109. Friedman SL. Mechanisms of hepatic fibrogenesis.
doi: 10.1007/s00109-005-0688-7 Gastroenterology. 2008;134:1655-1669.
101. Libby P, Plutzky J. Diabetic macrovascular disease: The doi: 10.1053/j.gastro.2008.03.003
glucose paradox? Circulation. 2002;106:2760-2763. 110. Miyahara T, Schrum L, Rippe R, et al. Peroxisome
doi: 10.1161/01.cir.0000037282.92395.ae proliferator-activated receptors and hepatic stellate cell
activation. J Biol Chem. 2000;275:35715-35722.
102. Rahbar S, Figarola JL. Novel inhibitors of advanced glycation
endproducts. Arch Biochem Biophys. 2003;419:63-79. doi: 10.1074/jbc.M006577200
doi: 10.1016/j.abb.2003.08.009 111. Gruzman A, Babai G, Sasson S. Adenosine monophosphate-
activated protein kinase (AMPK) as a new target for
103. Bonnefont-Rousselot D. Glucose and reactive oxygen antidiabetic drugs: A review on metabolic, pharmacological
species. Curr Opin Clin Nutr Metab Care. 2002;5:561-568. and chemical considerations. Rev Diabet Stud. 2009;6:13-36.
doi: 10.1097/00075197-200209000-00016 doi: 10.1900/RDS.2009.6.13
104. Lin J, Tang Y, Kang Q, Chen A. Curcumin eliminates the 112. You M, Matsumoto M, Pacold CM, Cho WK, Crabb DW.
inhibitory effect of advanced glycation end-products The role of AMP-activated protein kinase in the action of
(AGEs) on gene expression of AGE receptor-1 in hepatic ethanol in the liver. Gastroenterology. 2004;127:1798-1808.
stellate cells in vitro. Lab Invest. 2012;92:827-841.
doi: 10.1053/j.gastro.2004.09.049
doi: 10.1038/labinvest.2012.53
113. Kang Q, Chen A. Curcumin suppresses expression of low-
105. Lin J, Tang Y, Kang Q, Feng Y, Chen A. Curcumin inhibits density lipoprotein (LDL) receptor, leading to the inhibition
gene expression of receptor for advanced glycation end- of LDL-induced activation of hepatic stellate cells. Br J
products (RAGE) in hepatic stellate cells in vitro by elevating Pharmacol. 2009;157:1354-1367.
PPARgamma activity and attenuating oxidative stress. Br J
Pharmacol. 2012;166:2212-2227. doi: 10.1111/j.1476-5381.2009.00261.x
doi: 10.1111/j.1476-5381.2012.01910.x 114. Kang Q, Chen A. Curcumin inhibits srebp-2 expression in
activated hepatic stellate cells in vitro by reducing the activity
106. Tang Y, Chen A. Curcumin protects hepatic stellate cells of specificity protein-1. Endocrinology. 2009;150:5384-5394.
against leptin-induced activation in vitro by accumulating
intracellular lipids. Endocrinology. 2010;151:4168-4177. doi: 10.1210/en.2009-0517
doi: 10.1210/en.2010-0191 115. Buonomo AR, Scotto R, Nappa S, et al. The role of curcumin
in liver diseases. Arch Med Sci. 2019;15(6):1608-1620.
107. Zeng CH, Zeng P, Deng YH, et al. The effects of curcumin
derivative on experimental steatohepatitis. Zhonghua Gan doi: 10.5114/aoms.2018.73596
Zang Bing Za Zhi. 2011;19:454-459. 116. Pickich MB, Hargrove MW, Phillips CN, et al. Effect
of curcumin supplementation on serum expression of
108. Hasan ST, Zingg JM, Kwan P, Noble T, Smith D,
Meydani M. Curcumin modulation of high fat diet-induced select cytokines and chemokines in a female rat model of
atherosclerosis and steatohepatosis in LDL receptor deficient nonalcoholic steatohepatitis. BMC Res Notes. 2019;12(1):496.
mice. Atherosclerosis. 2014;232:40-51. doi: 10.1186/s13104-019-4540-5

Volume 3 Issue 3 (2024) 19 doi: 10.36922/gpd.3186